JP4652570B2 - Aavの構造タンパク質、その製造及び用途 - Google Patents

Aavの構造タンパク質、その製造及び用途 Download PDF

Info

Publication number
JP4652570B2
JP4652570B2 JP2000556035A JP2000556035A JP4652570B2 JP 4652570 B2 JP4652570 B2 JP 4652570B2 JP 2000556035 A JP2000556035 A JP 2000556035A JP 2000556035 A JP2000556035 A JP 2000556035A JP 4652570 B2 JP4652570 B2 JP 4652570B2
Authority
JP
Japan
Prior art keywords
structural protein
cells
cell
aav
aav2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000556035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002518050A (ja
JP2002518050A5 (cg-RX-API-DMAC7.html
Inventor
ハレク,ミヒャエル
リード,マルティーン
デリジュ,ジルベール
ジロ,アンヌ
Original Assignee
メディジーン・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディジーン・アクチェンゲゼルシャフト filed Critical メディジーン・アクチェンゲゼルシャフト
Publication of JP2002518050A publication Critical patent/JP2002518050A/ja
Publication of JP2002518050A5 publication Critical patent/JP2002518050A5/ja
Application granted granted Critical
Publication of JP4652570B2 publication Critical patent/JP4652570B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000556035A 1998-06-19 1999-06-21 Aavの構造タンパク質、その製造及び用途 Expired - Fee Related JP4652570B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19827457A DE19827457C1 (de) 1998-06-19 1998-06-19 Strukturprotein von AAV, seine Herstellung und Verwendung
DE19827457.2 1998-06-19
PCT/EP1999/004288 WO1999067393A2 (de) 1998-06-19 1999-06-21 Strukturprotein von aav, seine herstellung und verwendung

Publications (3)

Publication Number Publication Date
JP2002518050A JP2002518050A (ja) 2002-06-25
JP2002518050A5 JP2002518050A5 (cg-RX-API-DMAC7.html) 2006-08-03
JP4652570B2 true JP4652570B2 (ja) 2011-03-16

Family

ID=7871464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000556035A Expired - Fee Related JP4652570B2 (ja) 1998-06-19 1999-06-21 Aavの構造タンパク質、その製造及び用途

Country Status (10)

Country Link
US (2) US20070238684A1 (cg-RX-API-DMAC7.html)
EP (3) EP1783225B1 (cg-RX-API-DMAC7.html)
JP (1) JP4652570B2 (cg-RX-API-DMAC7.html)
AT (2) ATE338821T1 (cg-RX-API-DMAC7.html)
AU (1) AU765330B2 (cg-RX-API-DMAC7.html)
CA (1) CA2332115C (cg-RX-API-DMAC7.html)
DE (3) DE19827457C1 (cg-RX-API-DMAC7.html)
DK (1) DK1783225T3 (cg-RX-API-DMAC7.html)
ES (2) ES2352666T3 (cg-RX-API-DMAC7.html)
WO (1) WO1999067393A2 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
WO2000023955A1 (en) 1998-10-21 2000-04-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Virus-like particles for the induction of autoantibodies
DE19849643A1 (de) * 1998-10-29 2000-05-04 Deutsches Krebsforsch An das AAV-Kapsid bindender, den Zelltropismus verändernder Antikörper und Verfahren zum gerichteten Gentransfer
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US7314912B1 (en) 1999-06-21 2008-01-01 Medigene Aktiengesellschaft AAv scleroprotein, production and use thereof
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
DE19933719A1 (de) 1999-07-19 2001-01-25 Medigene Ag Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
US11136557B2 (en) 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
ES2822551T3 (es) 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
FI3265178T3 (fi) 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
JP6836999B2 (ja) 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California アデノ随伴ウイルス変異体及びその使用方法
CN109640949B (zh) 2016-07-29 2022-11-25 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体和其使用方法
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
KR20250023600A (ko) 2017-06-30 2025-02-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
MX2020001997A (es) 2017-08-28 2020-07-20 Univ California Variantes de capside de virus adenoasociado y metodos de uso de estas.
SG11202006298XA (en) * 2018-01-11 2020-07-29 Chameleon Biosciences Inc Immuno-evasive vectors and use for gene therapy
US11821009B2 (en) 2018-05-15 2023-11-21 Cornell University Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
KR20210126096A (ko) 2019-02-15 2021-10-19 상가모 테라퓨틱스, 인코포레이티드 재조합 aav를 제조하기 위한 조성물 및 방법
CA3132447A1 (en) * 2019-04-24 2020-10-29 Takara Bio Inc. Aav mutant having brain-targeting property
AU2020332268B2 (en) * 2019-07-02 2025-04-24 Trustees Of Tufts College Novel peptide, compositions and method for delivery of agents into cells and tissues
RU2751592C2 (ru) * 2019-08-22 2021-07-15 Общество С Ограниченной Ответственностью "Анабион" Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
AR126840A1 (es) * 2021-08-20 2023-11-22 Llc «Anabion» Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta
AR126839A1 (es) * 2021-08-20 2023-11-22 Llc «Anabion» Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
CN118480098B (zh) * 2023-09-20 2024-11-08 广州派真生物技术有限公司 腺相关病毒突变体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507383A (ja) * 1991-01-25 1994-08-25 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ラミニンのa鎖のドメイン6のポリペプチド
FR2716893B1 (fr) 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
WO1997038723A1 (en) * 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
US20010031463A1 (en) * 1997-09-02 2001-10-18 Jurgen Kleinschmidt Method for purifying and concentrating AAV-2 and antigen portions thereof
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
EP1135468B1 (en) * 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US7749492B2 (en) * 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
WO2002053703A2 (en) * 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
US20050106558A1 (en) * 2001-12-21 2005-05-19 Luca Perabo Library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism

Also Published As

Publication number Publication date
DE59915205D1 (de) 2010-10-28
US20070238684A1 (en) 2007-10-11
ES2352666T3 (es) 2011-02-22
EP1783225B1 (de) 2010-09-15
ES2273498T3 (es) 2007-05-01
DE19827457C1 (de) 2000-03-02
US20110052617A1 (en) 2011-03-03
CA2332115A1 (en) 1999-12-29
JP2002518050A (ja) 2002-06-25
WO1999067393A3 (de) 2000-03-30
EP1088075A2 (de) 2001-04-04
AU765330B2 (en) 2003-09-18
WO1999067393A2 (de) 1999-12-29
EP1088075B1 (de) 2006-09-06
DE59913833D1 (de) 2006-10-19
ATE481490T1 (de) 2010-10-15
EP1783226A1 (de) 2007-05-09
EP1783225A1 (de) 2007-05-09
DK1783225T3 (da) 2011-01-03
AU4614199A (en) 2000-01-10
ATE338821T1 (de) 2006-09-15
CA2332115C (en) 2011-08-09

Similar Documents

Publication Publication Date Title
US7314912B1 (en) AAv scleroprotein, production and use thereof
CA2332115C (en) Aav structural protein, its preparation and use
US7556965B2 (en) Structural protein of adeno-associated virus with modified antigenicity, its production and its use
US7285381B1 (en) Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same
US6962815B2 (en) AAV2 vectors and methods
US7749492B2 (en) AAV vectors and methods
US7172893B2 (en) Virus vectors and methods of making and administering the same
Muzyczka et al. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism
ES2467156T3 (es) Una biblioteca de genes estructurales modificados o de partículas modificadas de cápside útiles para la identificación de clones virales con tropismo celular deseado

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090316

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100720

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101118

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101216

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees